Cell and Gene Therapy Consumables Market, by Product Type (Kits and Buffers, Culture Medium, Cryopreservation Media, Diagnostic Assay, and Others), by Application/Therapeutics (Cardiovascular, Dermatology, Endocrine & Metabolic, Gastroenterology, Hematology & Oncology, Obstetrics, Critical Care, Immunology, Neuroscience, Respiratory, Urology, and Others), by Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019–2027
Market Overview/Industry Trends:
Cell and gene therapy involves the use of cells and genes for the treatment of diseases which are caused by mutations or errors in genes leading to a loss or change of function of RNA or protein molecules. Cell therapy involves the transfer of live cells with the appropriate tissue or organ restoration function into the patient, whereas gene therapy involves the transfer of genetic material, usually in a carrier or vector and the uptake of the gene into appropriate body cells. Cell therapy treats diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body while gene therapy focuses on the treatment of diseases by replacing, inactivating or introducing genes into cells, either in vivo ex vivo. Some of the factors characterizing the market growth are growing prevalence of target diseases (cardiovascular diseases, cancer, metabolic disorders, etc.), increasing awareness regarding gene therapy, rising demand for innovative medicines, introduction of effective guidelines regarding cell and gene therapies, and increasing funding for R&D activities. On the contrary, high costs associated with the treatment, unwanted immune responses from these therapy medicines, and difficulties in conducting randomized controlled trials (RCTs) for these therapies are anticipated to hinder the cell and gene therapy consumables market growth over the forecast period.
Worldwide rising prevalence of targeted diseases such as cardiovascular diseases (CVDs), cancer, impaired metabolic pathways, inherited blindness, metabolic disorders, and protein related disorders are likely to propel the demand for cell and gene therapy products during the assessment period. For instance, as per the data published by World Health Organization (WHO), in 2018, the global cancer burden was 18.1 million new cases and 9.6 million deaths as compared to 12.7 million new cases of cancer and the 7.6 million cancer deaths worldwide during 2008. The WHO reported that cardiovascular diseases are the major cause of death worldwide, causing an estimated 17.9 million deaths every year. Thus, this is fostering the demand for cell and gene therapy consumables market. In terms of revenue, the global cell and gene therapy consumables market was estimated to be US$ 641.22 Mn in 2018 and is expected to reach US$ 6,999.35 Mn by 2027 growing at a CAGR of 30.43% over the forecast period. The study analyzes the market in terms of revenue across all the major regions, which has been further bifurcated into countries.
Cell and Gene Therapy Consumables Market Revenue & Forecast, (US$ Million), 2015–2027
Product Type Outlook:
The kits and buffers segment accounted for substantial share of cell and gene therapy consumables market in 2018 owing to its comparatively higher adoption and repetitive purchase during cell and gene therapies. Technological developments in kits for example, GE Healthcare offers disposable or single-use kits and bioreactor bags which support automated and functionally closed cell processing across the workflow are supporting the dominance of the segment. Some of the commercially available kits are Autologous and Allogeneic Cell Therapy Kits and Nontherapeutic Research and Development Kits (Akron Biotech) and RoboSep Buffer (STEMCELL Technologies Inc.).
Application/Therapeutics Outlook:
The cardiovascular segment dominated the cell and gene therapy consumables market in 2018 and is expected to maintain its status quo over the review period due to globally rising burden of CVDs along with growing demand for cell and gene therapy to treat cardiovascular diseases, namely, coronary artery disease (CAD) or coronary heart disease (CHD), stroke, cardiac arrhythmias, and hypertension. The WHO stated that coronary heart disease is now the leading cause of death worldwide. About 3.8 million men and 3.4 million women die each year from coronary heart disease across the world. The most advances in medicine such as the use of stem cell and gene therapy to repair all forms of acute and chronic illness are about to nurture the market growth in the near future.The critical care segment is expected to exhibit comparatively higher CAGR over the forecast period on account of rising use of gene therapy in critical care medicines to treat several conditions such as severe sepsis and the acute respiratory distress syndrome (ARDS), including acute lung injury (ALI).
Competitive Landscape:
The report provides both qualitative and quantitative research of cell and gene therapy consumables market as well as provides comprehensive insights and development methods adopted by the prominent market players. Some of the key market participants in the cell and gene therapy consumables market are Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook Medical, Dendreon Pharmaceuticals LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc, Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, ViroMed Co., Ltd., and Vitrolife. These players have adopted growth strategies such as new product launches, partnerships, collaborations, mergers and acquisitions, and joint ventures (JVs) in order to gain a competitive advantage. For instance, in May 2019, General Electric launched chronicle automation software for cell therapy. In October 2018, bluebird bio, Inc. received an approval from European Medicines Agency (EMA) for its investigational LentiGlobin gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassemia (TDT).
For each company, the report studies their global presence, competitors and product offerings, among others.
Global Cell and Gene Therapy Consumables Market:
- By Product Type
- Kits and Buffers
- Culture Medium
- Natural Media
- Plasma
- Serum
- Lymph
- Human Placental Cord Serum
- Amniotic Fluid
- Others
- Artificial Media
- MEM
- RPMI
- PBS
- DPBS
- HBSS
- EBSS
- Others
- Natural Media
- Cryopreservation Media
- Diagnostic Assay
- Others
- By Application/Therapeutics
- Cardiovascular
- Dermatology
- Endocrine and Metabolic
- Gastroenterology
- Hematology and Oncology
- Obstetrics
- Critical Care
- Immunology
- Neuroscience
- Respiratory
- Urology
- Others
- By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Cell and Gene Therapy Consumables Market
6. Market Synopsis: Cell
and Gene Therapy Consumables Market
7. Cell and Gene Therapy Consumables Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Cell and Gene Therapy Consumables Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Cell and Gene Therapy Consumables Market
7.6. Porter’s
Five Force Analysis
7.7. PESTEL
Analysis
8. Global Cell and Gene Therapy Consumables Market Analysis and
Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Cell and Gene Therapy Consumables Market Revenue (US$ Mn)
8.2. Global
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
8.2.1. Kits and
Buffers
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. Culture
Medium (Definition, Market Estimation and Penetration, 2013 – 2018, Market
Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Natural Media, Artificial
Media)
8.2.2.1. Natural
Media
8.2.2.1.1. Plasma
8.2.2.1.2. Serum
8.2.2.1.3. Lymph
8.2.2.1.4. Human
Placental Cord Serum
8.2.2.1.5. Amniotic
Fluid
8.2.2.1.6. Others
8.2.2.2. Artificial
Media
8.2.2.2.1. MEM
8.2.2.2.2. RPMI
8.2.2.2.3. PBS
8.2.2.2.4. DPBS
8.2.2.2.5. HBSS
8.2.2.2.6. EBSS
8.2.2.2.7. Others
8.2.3. Cryopreservation
Media
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Diagnostic
Assay
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2013 – 2018
8.2.4.3. Market
Forecast, 2019 – 2027
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2013 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2013 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2013 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2013 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2013 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.2.5. Others
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2013 – 2018
8.2.5.3. Market
Forecast, 2019 – 2027
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2013 – 2018
8.2.5.5.1.2. Market
Forecast, 2019 – 2027
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2013 – 2018
8.2.5.5.2.2. Market
Forecast, 2019 – 2027
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2013 – 2018
8.2.5.5.3.2. Market
Forecast, 2019 – 2027
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2013 – 2018
8.2.5.5.4.2. Market
Forecast, 2019 – 2027
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2013 – 2018
8.2.5.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key
Segment for Channeling Investments
8.3.1. By
Product Type
9. Global Cell and Gene Therapy Consumables Market Analysis and Forecasts,
2019 – 2027
9.1. Overview
9.2. Global
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
9.2.1. Cardiovascular
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Dermatology
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2013 – 2018
9.2.2.3. Market
Forecast, 2019 – 2027
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2013 – 2018
9.2.2.5.1.2. Market
Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2013 – 2018
9.2.2.5.2.2. Market
Forecast, 2019 – 2027
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2013 – 2018
9.2.2.5.3.2. Market
Forecast, 2019 – 2027
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2013 – 2018
9.2.2.5.4.2. Market
Forecast, 2019 – 2027
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2013 – 2018
9.2.2.5.5.2. Market
Forecast, 2019 – 2027
9.2.3. Endocrine
and Metabolic
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.2.4. Gastroenterology
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2013 – 2018
9.2.4.3. Market
Forecast, 2019 – 2027
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2013 – 2018
9.2.4.5.1.2. Market
Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2013 – 2018
9.2.4.5.2.2. Market
Forecast, 2019 – 2027
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2013 – 2018
9.2.4.5.3.2. Market
Forecast, 2019 – 2027
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2013 – 2018
9.2.4.5.4.2. Market
Forecast, 2019 – 2027
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2013 – 2018
9.2.4.5.5.2. Market
Forecast, 2019 – 2027
9.2.5. Hematology
and Oncology
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2013 – 2018
9.2.5.3. Market
Forecast, 2019 – 2027
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2013 – 2018
9.2.5.5.1.2. Market
Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2013 – 2018
9.2.5.5.2.2. Market
Forecast, 2019 – 2027
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2013 – 2018
9.2.5.5.3.2. Market
Forecast, 2019 – 2027
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2013 – 2018
9.2.5.5.4.2. Market
Forecast, 2019 – 2027
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2013 – 2018
9.2.5.5.5.2. Market
Forecast, 2019 – 2027
9.2.6. Obstetrics
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2013 – 2018
9.2.6.3. Market
Forecast, 2019 – 2027
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2013 – 2018
9.2.6.5.1.2. Market
Forecast, 2019 – 2027
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2013 – 2018
9.2.6.5.2.2. Market
Forecast, 2019 – 2027
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2013 – 2018
9.2.6.5.3.2. Market
Forecast, 2019 – 2027
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2013 – 2018
9.2.6.5.4.2. Market
Forecast, 2019 – 2027
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2013 – 2018
9.2.6.5.5.2. Market
Forecast, 2019 – 2027
9.2.7. Critical
Care
9.2.7.1. Definition
9.2.7.2. Market
Estimation and Penetration, 2013 – 2018
9.2.7.3. Market
Forecast, 2019 – 2027
9.2.7.4. Compound
Annual Growth Rate (CAGR)
9.2.7.5. Regional
Bifurcation
9.2.7.5.1. North
America
9.2.7.5.1.1. Market
Estimation, 2013 – 2018
9.2.7.5.1.2. Market
Forecast, 2019 – 2027
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2013 – 2018
9.2.7.5.2.2. Market
Forecast, 2019 – 2027
9.2.7.5.3. Asia
Pacific
9.2.7.5.3.1. Market
Estimation, 2013 – 2018
9.2.7.5.3.2. Market
Forecast, 2019 – 2027
9.2.7.5.4. Middle
East and Africa
9.2.7.5.4.1. Market
Estimation, 2013 – 2018
9.2.7.5.4.2. Market
Forecast, 2019 – 2027
9.2.7.5.5. Latin
America
9.2.7.5.5.1. Market
Estimation, 2013 – 2018
9.2.7.5.5.2. Market
Forecast, 2019 – 2027
9.2.8. Immunology
9.2.8.1. Definition
9.2.8.2. Market
Estimation and Penetration, 2013 – 2018
9.2.8.3. Market
Forecast, 2019 – 2027
9.2.8.4. Compound
Annual Growth Rate (CAGR)
9.2.8.5. Regional
Bifurcation
9.2.8.5.1. North
America
9.2.8.5.1.1. Market
Estimation, 2013 – 2018
9.2.8.5.1.2. Market
Forecast, 2019 – 2027
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2013 – 2018
9.2.8.5.2.2. Market
Forecast, 2019 – 2027
9.2.8.5.3. Asia
Pacific
9.2.8.5.3.1. Market
Estimation, 2013 – 2018
9.2.8.5.3.2. Market
Forecast, 2019 – 2027
9.2.8.5.4. Middle
East and Africa
9.2.8.5.4.1. Market
Estimation, 2013 – 2018
9.2.8.5.4.2. Market
Forecast, 2019 – 2027
9.2.8.5.5. Latin
America
9.2.8.5.5.1. Market
Estimation, 2013 – 2018
9.2.8.5.5.2. Market
Forecast, 2019 – 2027
9.2.9. Neuroscience
9.2.9.1. Definition
9.2.9.2. Market
Estimation and Penetration, 2013 – 2018
9.2.9.3. Market
Forecast, 2019 – 2027
9.2.9.4. Compound
Annual Growth Rate (CAGR)
9.2.9.5. Regional
Bifurcation
9.2.9.5.1. North
America
9.2.9.5.1.1. Market
Estimation, 2013 – 2018
9.2.9.5.1.2. Market
Forecast, 2019 – 2027
9.2.9.5.2. Europe
9.2.9.5.2.1. Market
Estimation, 2013 – 2018
9.2.9.5.2.2. Market
Forecast, 2019 – 2027
9.2.9.5.3. Asia
Pacific
9.2.9.5.3.1. Market
Estimation, 2013 – 2018
9.2.9.5.3.2. Market
Forecast, 2019 – 2027
9.2.9.5.4. Middle
East and Africa
9.2.9.5.4.1. Market
Estimation, 2013 – 2018
9.2.9.5.4.2. Market
Forecast, 2019 – 2027
9.2.9.5.5. Latin
America
9.2.9.5.5.1. Market
Estimation, 2013 – 2018
9.2.9.5.5.2. Market
Forecast, 2019 – 2027
9.2.10. Respiratory
9.2.10.1. Definition
9.2.10.2. Market
Estimation and Penetration, 2013 – 2018
9.2.10.3. Market
Forecast, 2019 – 2027
9.2.10.4. Compound
Annual Growth Rate (CAGR)
9.2.10.5. Regional
Bifurcation
9.2.10.5.1. North
America
9.2.10.5.1.1. Market
Estimation, 2013 – 2018
9.2.10.5.1.2. Market
Forecast, 2019 – 2027
9.2.10.5.2. Europe
9.2.10.5.2.1. Market
Estimation, 2013 – 2018
9.2.10.5.2.2. Market
Forecast, 2019 – 2027
9.2.10.5.3. Asia
Pacific
9.2.10.5.3.1. Market
Estimation, 2013 – 2018
9.2.10.5.3.2. Market
Forecast, 2019 – 2027
9.2.10.5.4. Middle
East and Africa
9.2.10.5.4.1. Market
Estimation, 2013 – 2018
9.2.10.5.4.2. Market
Forecast, 2019 – 2027
9.2.10.5.5. Latin
America
9.2.10.5.5.1. Market
Estimation, 2013 – 2018
9.2.10.5.5.2. Market
Forecast, 2019 – 2027
9.2.11. Urology
9.2.11.1. Definition
9.2.11.2. Market
Estimation and Penetration, 2013 – 2018
9.2.11.3. Market
Forecast, 2019 – 2027
9.2.11.4. Compound
Annual Growth Rate (CAGR)
9.2.11.5. Regional
Bifurcation
9.2.11.5.1. North
America
9.2.11.5.1.1. Market
Estimation, 2013 – 2018
9.2.11.5.1.2. Market
Forecast, 2019 – 2027
9.2.11.5.2. Europe
9.2.11.5.2.1. Market
Estimation, 2013 – 2018
9.2.11.5.2.2. Market
Forecast, 2019 – 2027
9.2.11.5.3. Asia
Pacific
9.2.11.5.3.1. Market
Estimation, 2013 – 2018
9.2.11.5.3.2. Market
Forecast, 2019 – 2027
9.2.11.5.4. Middle
East and Africa
9.2.11.5.4.1. Market
Estimation, 2013 – 2018
9.2.11.5.4.2. Market
Forecast, 2019 – 2027
9.2.11.5.5. Latin
America
9.2.11.5.5.1. Market
Estimation, 2013 – 2018
9.2.11.5.5.2. Market
Forecast, 2019 – 2027
9.2.12. Others
9.2.12.1. Definition
9.2.12.2. Market
Estimation and Penetration, 2013 – 2018
9.2.12.3. Market
Forecast, 2019 – 2027
9.2.12.4. Compound
Annual Growth Rate (CAGR)
9.2.12.5. Regional
Bifurcation
9.2.12.5.1. North
America
9.2.12.5.1.1. Market
Estimation, 2013 – 2018
9.2.12.5.1.2. Market
Forecast, 2019 – 2027
9.2.12.5.2. Europe
9.2.12.5.2.1. Market
Estimation, 2013 – 2018
9.2.12.5.2.2. Market
Forecast, 2019 – 2027
9.2.12.5.3. Asia
Pacific
9.2.12.5.3.1. Market
Estimation, 2013 – 2018
9.2.12.5.3.2. Market
Forecast, 2019 – 2027
9.2.12.5.4. Middle
East and Africa
9.2.12.5.4.1. Market
Estimation, 2013 – 2018
9.2.12.5.4.2. Market
Forecast, 2019 – 2027
9.2.12.5.5. Latin
America
9.2.12.5.5.1. Market
Estimation, 2013 – 2018
9.2.12.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application/Therapeutics
10. North America Cell and Gene Therapy Consumables Market
Analysis and Forecasts, 2019 - 2027
10.1. Overview
10.1.1. North
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn)
10.2. North
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
10.2.1. Kits
and Buffers
10.2.2. Culture
Medium
10.2.2.1. Natural
Media
10.2.2.1.1. Plasma
10.2.2.1.2. Serum
10.2.2.1.3. Lymph
10.2.2.1.4. Human
Placental Cord Serum
10.2.2.1.5. Amniotic
Fluid
10.2.2.1.6. Others
10.2.2.2. Artificial
Media
10.2.2.2.1. MEM
10.2.2.2.2. RPMI
10.2.2.2.3. PBS
10.2.2.2.4. DPBS
10.2.2.2.5. HBSS
10.2.2.2.6. EBSS
10.2.2.2.7. Others
10.2.3. Cryopreservation
Media
10.2.4. Diagnostic
Assay
10.2.5. Others
10.3. North
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
10.3.1. Cardiovascular
10.3.2. Dermatology
10.3.3. Endocrine
and Metabolic
10.3.4. Gastroenterology
10.3.5. Hematology
and Oncology
10.3.6. Obstetrics
10.3.7. Critical
Care
10.3.8. Immunology
10.3.9. Neuroscience
10.3.10. Respiratory
10.3.11. Urology
10.3.12. Others
10.4. North
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S Cell
and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Product
Type
10.4.1.1.1. Kits
and Buffers
10.4.1.1.2. Culture
Medium
10.4.1.1.2.1. Natural
Media
10.4.1.1.2.1.1. Plasma
10.4.1.1.2.1.2. Serum
10.4.1.1.2.1.3. Lymph
10.4.1.1.2.1.4. Human Placental Cord Serum
10.4.1.1.2.1.5. Amniotic Fluid
10.4.1.1.2.1.6. Others
10.4.1.1.2.2. Artificial
Media
10.4.1.1.2.2.1. MEM
10.4.1.1.2.2.2. RPMI
10.4.1.1.2.2.3. PBS
10.4.1.1.2.2.4. DPBS
10.4.1.1.2.2.5. HBSS
10.4.1.1.2.2.6. EBSS
10.4.1.1.2.2.7. Others
10.4.1.1.3. Cryopreservation
Media
10.4.1.1.4. Diagnostic
Assay
10.4.1.1.5. Others
10.4.1.2. U.S
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
10.4.1.2.1. Cardiovascular
10.4.1.2.2. Dermatology
10.4.1.2.3. Endocrine
and Metabolic
10.4.1.2.4. Gastroenterology
10.4.1.2.5. Hematology
and Oncology
10.4.1.2.6. Obstetrics
10.4.1.2.7. Critical
Care
10.4.1.2.8. Immunology
10.4.1.2.9. Neuroscience
10.4.1.2.10. Respiratory
10.4.1.2.11. Urology
10.4.1.2.12. Others
10.4.2. Canada
10.4.2.1. Canada
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
10.4.2.1.1. Kits
and Buffers
10.4.2.1.2. Culture
Medium
10.4.2.1.2.1. Natural
Media
10.4.2.1.2.1.1. Plasma
10.4.2.1.2.1.2. Serum
10.4.2.1.2.1.3. Lymph
10.4.2.1.2.1.4. Human Placental Cord Serum
10.4.2.1.2.1.5. Amniotic Fluid
10.4.2.1.2.1.6. Others
10.4.2.1.2.2. Artificial
Media
10.4.2.1.2.2.1. MEM
10.4.2.1.2.2.2. RPMI
10.4.2.1.2.2.3. PBS
10.4.2.1.2.2.4. DPBS
10.4.2.1.2.2.5. HBSS
10.4.2.1.2.2.6. EBSS
10.4.2.1.2.2.7. Others
10.4.2.1.3. Cryopreservation
Media
10.4.2.1.4. Diagnostic
Assay
10.4.2.1.5. Others
10.4.2.2. Canada
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
10.4.2.2.1. Cardiovascular
10.4.2.2.2. Dermatology
10.4.2.2.3. Endocrine
and Metabolic
10.4.2.2.4. Gastroenterology
10.4.2.2.5. Hematology
and Oncology
10.4.2.2.6. Obstetrics
10.4.2.2.7. Critical
Care
10.4.2.2.8. Immunology
10.4.2.2.9. Neuroscience
10.4.2.2.10. Respiratory
10.4.2.2.11. Urology
10.4.2.2.12. Others
10.4.3. Mexico
10.4.3.1. Mexico
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
10.4.3.1.1. Kits
and Buffers
10.4.3.1.2. Culture
Medium
10.4.3.1.2.1. Natural
Media
10.4.3.1.2.1.1. Plasma
10.4.3.1.2.1.2. Serum
10.4.3.1.2.1.3. Lymph
10.4.3.1.2.1.4. Human Placental Cord Serum
10.4.3.1.2.1.5. Amniotic Fluid
10.4.3.1.2.1.6. Others
10.4.3.1.2.2. Artificial
Media
10.4.3.1.2.2.1. MEM
10.4.3.1.2.2.2. RPMI
10.4.3.1.2.2.3. PBS
10.4.3.1.2.2.4. DPBS
10.4.3.1.2.2.5. HBSS
10.4.3.1.2.2.6. EBSS
10.4.3.1.2.2.7. Others
10.4.3.1.3. Cryopreservation
Media
10.4.3.1.4. Diagnostic
Assay
10.4.3.1.5. Others
10.4.3.2. Mexico
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
10.4.3.2.1. Cardiovascular
10.4.3.2.2. Dermatology
10.4.3.2.3. Endocrine
and Metabolic
10.4.3.2.4. Gastroenterology
10.4.3.2.5. Hematology
and Oncology
10.4.3.2.6. Obstetrics
10.4.3.2.7. Critical
Care
10.4.3.2.8. Immunology
10.4.3.2.9. Neuroscience
10.4.3.2.10. Respiratory
10.4.3.2.11. Urology
10.4.3.2.12. Others
10.4.4. Rest of
North America
10.4.4.1. Rest
of North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
10.4.4.1.1. Kits
and Buffers
10.4.4.1.2. Culture
Medium
10.4.4.1.2.1. Natural
Media
10.4.4.1.2.1.1. Plasma
10.4.4.1.2.1.2. Serum
10.4.4.1.2.1.3. Lymph
10.4.4.1.2.1.4. Human Placental Cord Serum
10.4.4.1.2.1.5. Amniotic Fluid
10.4.4.1.2.1.6. Others
10.4.4.1.2.2. Artificial
Media
10.4.4.1.2.2.1. MEM
10.4.4.1.2.2.2. RPMI
10.4.4.1.2.2.3. PBS
10.4.4.1.2.2.4. DPBS
10.4.4.1.2.2.5. HBSS
10.4.4.1.2.2.6. EBSS
10.4.4.1.2.2.7. Others
10.4.4.1.3. Cryopreservation
Media
10.4.4.1.4. Diagnostic
Assay
10.4.4.1.5. Others
10.4.4.2. Rest
of North America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
10.4.4.2.1. Cardiovascular
10.4.4.2.2. Dermatology
10.4.4.2.3. Endocrine
and Metabolic
10.4.4.2.4. Gastroenterology
10.4.4.2.5. Hematology
and Oncology
10.4.4.2.6. Obstetrics
10.4.4.2.7. Critical
Care
10.4.4.2.8. Immunology
10.4.4.2.9. Neuroscience
10.4.4.2.10. Respiratory
10.4.4.2.11. Urology
10.4.4.2.12. Others
10.5. Key
Segment for Channeling Investments
10.5.1. By
Country
10.5.2. By
Product Type
10.5.3. By
Application/Therapeutics
11. Europe Cell and Gene Therapy Consumables Market Analysis and
Forecasts, 2019 - 2027
11.1. Overview
11.1.1. Europe
Cell and Gene Therapy Consumables Market Revenue (US$ Mn)
11.2. Europe
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
11.2.1. Kits
and Buffers
11.2.2. Culture
Medium
11.2.2.1. Natural
Media
11.2.2.1.1. Plasma
11.2.2.1.2. Serum
11.2.2.1.3. Lymph
11.2.2.1.4. Human
Placental Cord Serum
11.2.2.1.5. Amniotic
Fluid
11.2.2.1.6. Others
11.2.2.2. Artificial
Media
11.2.2.2.1. MEM
11.2.2.2.2. RPMI
11.2.2.2.3. PBS
11.2.2.2.4. DPBS
11.2.2.2.5. HBSS
11.2.2.2.6. EBSS
11.2.2.2.7. Others
11.2.3. Cryopreservation
Media
11.2.4. Diagnostic
Assay
11.2.5. Others
11.3. Europe
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
11.3.1. Cardiovascular
11.3.2. Dermatology
11.3.3. Endocrine
and Metabolic
11.3.4. Gastroenterology
11.3.5. Hematology
and Oncology
11.3.6. Obstetrics
11.3.7. Critical
Care
11.3.8. Immunology
11.3.9. Neuroscience
11.3.10. Respiratory
11.3.11. Urology
11.3.12. Others
11.4. Europe
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Country
11.4.1. France
11.4.1.1. France
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
11.4.1.1.1. Kits
and Buffers
11.4.1.1.2. Culture
Medium
11.4.1.1.2.1. Natural
Media
11.4.1.1.2.1.1. Plasma
11.4.1.1.2.1.2. Serum
11.4.1.1.2.1.3. Lymph
11.4.1.1.2.1.4. Human Placental Cord Serum
11.4.1.1.2.1.5. Amniotic Fluid
11.4.1.1.2.1.6. Others
11.4.1.1.2.2. Artificial
Media
11.4.1.1.2.2.1. MEM
11.4.1.1.2.2.2. RPMI
11.4.1.1.2.2.3. PBS
11.4.1.1.2.2.4. DPBS
11.4.1.1.2.2.5. HBSS
11.4.1.1.2.2.6. EBSS
11.4.1.1.2.2.7. Others
11.4.1.1.3. Cryopreservation
Media
11.4.1.1.4. Diagnostic
Assay
11.4.1.1.5. Others
11.4.1.2. France
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
11.4.1.2.1. Cardiovascular
11.4.1.2.2. Dermatology
11.4.1.2.3. Endocrine
and Metabolic
11.4.1.2.4. Gastroenterology
11.4.1.2.5. Hematology
and Oncology
11.4.1.2.6. Obstetrics
11.4.1.2.7. Critical
Care
11.4.1.2.8. Immunology
11.4.1.2.9. Neuroscience
11.4.1.2.10. Respiratory
11.4.1.2.11. Urology
11.4.1.2.12. Others
11.4.2. The UK
11.4.2.1. The
UK Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
11.4.2.1.1. Kits
and Buffers
11.4.2.1.2. Culture
Medium
11.4.2.1.2.1. Natural
Media
11.4.2.1.2.1.1. Plasma
11.4.2.1.2.1.2. Serum
11.4.2.1.2.1.3. Lymph
11.4.2.1.2.1.4. Human Placental Cord Serum
11.4.2.1.2.1.5. Amniotic Fluid
11.4.2.1.2.1.6. Others
11.4.2.1.2.2. Artificial
Media
11.4.2.1.2.2.1. MEM
11.4.2.1.2.2.2. RPMI
11.4.2.1.2.2.3. PBS
11.4.2.1.2.2.4. DPBS
11.4.2.1.2.2.5. HBSS
11.4.2.1.2.2.6. EBSS
11.4.2.1.2.2.7. Others
11.4.2.1.3. Cryopreservation
Media
11.4.2.1.4. Diagnostic
Assay
11.4.2.1.5. Others
11.4.2.2. The
UK Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
11.4.2.2.1. Cardiovascular
11.4.2.2.2. Dermatology
11.4.2.2.3. Endocrine
and Metabolic
11.4.2.2.4. Gastroenterology
11.4.2.2.5. Hematology
and Oncology
11.4.2.2.6. Obstetrics
11.4.2.2.7. Critical
Care
11.4.2.2.8. Immunology
11.4.2.2.9. Neuroscience
11.4.2.2.10. Respiratory
11.4.2.2.11. Urology
11.4.2.2.12. Others
11.4.3. Spain
11.4.3.1. Spain
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
11.4.3.1.1. Kits
and Buffers
11.4.3.1.2. Culture
Medium
11.4.3.1.2.1. Natural
Media
11.4.3.1.2.1.1. Plasma
11.4.3.1.2.1.2. Serum
11.4.3.1.2.1.3. Lymph
11.4.3.1.2.1.4. Human Placental Cord Serum
11.4.3.1.2.1.5. Amniotic Fluid
11.4.3.1.2.1.6. Others
11.4.3.1.2.2. Artificial
Media
11.4.3.1.2.2.1. MEM
11.4.3.1.2.2.2. RPMI
11.4.3.1.2.2.3. PBS
11.4.3.1.2.2.4. DPBS
11.4.3.1.2.2.5. HBSS
11.4.3.1.2.2.6. EBSS
11.4.3.1.2.2.7. Others
11.4.3.1.3. Cryopreservation
Media
11.4.3.1.4. Diagnostic
Assay
11.4.3.1.5. Others
11.4.3.2. Spain
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
11.4.3.2.1. Cardiovascular
11.4.3.2.2. Dermatology
11.4.3.2.3. Endocrine
and Metabolic
11.4.3.2.4. Gastroenterology
11.4.3.2.5. Hematology
and Oncology
11.4.3.2.6. Obstetrics
11.4.3.2.7. Critical
Care
11.4.3.2.8. Immunology
11.4.3.2.9. Neuroscience
11.4.3.2.10. Respiratory
11.4.3.2.11. Urology
11.4.3.2.12. Others
11.4.4. Germany
11.4.4.1. Germany
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
11.4.4.1.1. Kits
and Buffers
11.4.4.1.2. Culture
Medium
11.4.4.1.2.1. Natural
Media
11.4.4.1.2.1.1. Plasma
11.4.4.1.2.1.2. Serum
11.4.4.1.2.1.3. Lymph
11.4.4.1.2.1.4. Human Placental Cord Serum
11.4.4.1.2.1.5. Amniotic Fluid
11.4.4.1.2.1.6. Others
11.4.4.1.2.2. Artificial
Media
11.4.4.1.2.2.1. MEM
11.4.4.1.2.2.2. RPMI
11.4.4.1.2.2.3. PBS
11.4.4.1.2.2.4. DPBS
11.4.4.1.2.2.5. HBSS
11.4.4.1.2.2.6. EBSS
11.4.4.1.2.2.7. Others
11.4.4.1.3. Cryopreservation
Media
11.4.4.1.4. Diagnostic
Assay
11.4.4.1.5. Others
11.4.4.2. Germany
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
11.4.4.2.1. Cardiovascular
11.4.4.2.2. Dermatology
11.4.4.2.3. Endocrine
and Metabolic
11.4.4.2.4. Gastroenterology
11.4.4.2.5. Hematology
and Oncology
11.4.4.2.6. Obstetrics
11.4.4.2.7. Critical
Care
11.4.4.2.8. Immunology
11.4.4.2.9. Neuroscience
11.4.4.2.10. Respiratory
11.4.4.2.11. Urology
11.4.4.2.12. Others
11.4.5. Italy
11.4.5.1. Italy
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
11.4.5.1.1. Kits
and Buffers
11.4.5.1.2. Culture
Medium
11.4.5.1.2.1. Natural
Media
11.4.5.1.2.1.1. Plasma
11.4.5.1.2.1.2. Serum
11.4.5.1.2.1.3. Lymph
11.4.5.1.2.1.4. Human Placental Cord Serum
11.4.5.1.2.1.5. Amniotic Fluid
11.4.5.1.2.1.6. Others
11.4.5.1.2.2. Artificial
Media
11.4.5.1.2.2.1. MEM
11.4.5.1.2.2.2. RPMI
11.4.5.1.2.2.3. PBS
11.4.5.1.2.2.4. DPBS
11.4.5.1.2.2.5. HBSS
11.4.5.1.2.2.6. EBSS
11.4.5.1.2.2.7. Others
11.4.5.1.3. Cryopreservation
Media
11.4.5.1.4. Diagnostic
Assay
11.4.5.1.5. Others
11.4.5.2. Italy
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
11.4.5.2.1. Cardiovascular
11.4.5.2.2. Dermatology
11.4.5.2.3. Endocrine
and Metabolic
11.4.5.2.4. Gastroenterology
11.4.5.2.5. Hematology
and Oncology
11.4.5.2.6. Obstetrics
11.4.5.2.7. Critical
Care
11.4.5.2.8. Immunology
11.4.5.2.9. Neuroscience
11.4.5.2.10. Respiratory
11.4.5.2.11. Urology
11.4.5.2.12. Others
11.4.6. Nordic
Countries
11.4.6.1. Nordic
Countries Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
11.4.6.1.1. Kits
and Buffers
11.4.6.1.2. Culture
Medium
11.4.6.1.2.1. Natural
Media
11.4.6.1.2.1.1. Plasma
11.4.6.1.2.1.2. Serum
11.4.6.1.2.1.3. Lymph
11.4.6.1.2.1.4. Human Placental Cord Serum
11.4.6.1.2.1.5. Amniotic Fluid
11.4.6.1.2.1.6. Others
11.4.6.1.2.2. Artificial
Media
11.4.6.1.2.2.1. MEM
11.4.6.1.2.2.2. RPMI
11.4.6.1.2.2.3. PBS
11.4.6.1.2.2.4. DPBS
11.4.6.1.2.2.5. HBSS
11.4.6.1.2.2.6. EBSS
11.4.6.1.2.2.7. Others
11.4.6.1.3. Cryopreservation
Media
11.4.6.1.4. Diagnostic
Assay
11.4.6.1.5. Others
11.4.6.2. Nordic
Countries Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
11.4.6.2.1. Cardiovascular
11.4.6.2.2. Dermatology
11.4.6.2.3. Endocrine
and Metabolic
11.4.6.2.4. Gastroenterology
11.4.6.2.5. Hematology
and Oncology
11.4.6.2.6. Obstetrics
11.4.6.2.7. Critical
Care
11.4.6.2.8. Immunology
11.4.6.2.9. Neuroscience
11.4.6.2.10. Respiratory
11.4.6.2.11. Urology
11.4.6.2.12. Others
11.4.6.3. Nordic
Countries Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux
Union
11.4.7.1. Benelux
Union Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Product Type
11.4.7.1.1. Kits
and Buffers
11.4.7.1.2. Culture
Medium
11.4.7.1.2.1. Natural
Media
11.4.7.1.2.1.1. Plasma
11.4.7.1.2.1.2. Serum
11.4.7.1.2.1.3. Lymph
11.4.7.1.2.1.4. Human Placental Cord Serum
11.4.7.1.2.1.5. Amniotic Fluid
11.4.7.1.2.1.6. Others
11.4.7.1.2.2. Artificial
Media
11.4.7.1.2.2.1. MEM
11.4.7.1.2.2.2. RPMI
11.4.7.1.2.2.3. PBS
11.4.7.1.2.2.4. DPBS
11.4.7.1.2.2.5. HBSS
11.4.7.1.2.2.6. EBSS
11.4.7.1.2.2.7. Others
11.4.7.1.3. Cryopreservation
Media
11.4.7.1.4. Diagnostic
Assay
11.4.7.1.5. Others
11.4.7.2. Benelux
Union Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Application/Therapeutics
11.4.7.2.1. Cardiovascular
11.4.7.2.2. Dermatology
11.4.7.2.3. Endocrine
and Metabolic
11.4.7.2.4. Gastroenterology
11.4.7.2.5. Hematology
and Oncology
11.4.7.2.6. Obstetrics
11.4.7.2.7. Critical
Care
11.4.7.2.8. Immunology
11.4.7.2.9. Neuroscience
11.4.7.2.10. Respiratory
11.4.7.2.11. Urology
11.4.7.2.12. Others
11.4.7.3. Benelux
Union Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The
Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of
Europe
11.4.8.1. Rest
of Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
11.4.8.1.1. Kits
and Buffers
11.4.8.1.2. Culture
Medium
11.4.8.1.2.1. Natural
Media
11.4.8.1.2.1.1. Plasma
11.4.8.1.2.1.2. Serum
11.4.8.1.2.1.3. Lymph
11.4.8.1.2.1.4. Human Placental Cord Serum
11.4.8.1.2.1.5. Amniotic Fluid
11.4.8.1.2.1.6. Others
11.4.8.1.2.2. Artificial
Media
11.4.8.1.2.2.1. MEM
11.4.8.1.2.2.2. RPMI
11.4.8.1.2.2.3. PBS
11.4.8.1.2.2.4. DPBS
11.4.8.1.2.2.5. HBSS
11.4.8.1.2.2.6. EBSS
11.4.8.1.2.2.7. Others
11.4.8.1.3. Cryopreservation
Media
11.4.8.1.4. Diagnostic
Assay
11.4.8.1.5. Others
11.4.8.2. Rest
of Europe Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
11.4.8.2.1. Cardiovascular
11.4.8.2.2. Dermatology
11.4.8.2.3. Endocrine
and Metabolic
11.4.8.2.4. Gastroenterology
11.4.8.2.5. Hematology
and Oncology
11.4.8.2.6. Obstetrics
11.4.8.2.7. Critical
Care
11.4.8.2.8. Immunology
11.4.8.2.9. Neuroscience
11.4.8.2.10. Respiratory
11.4.8.2.11. Urology
11.4.8.2.12. Others
11.5. Key
Segment for Channeling Investments
11.5.1. By
Country
11.5.2. By
Product Type
11.5.3. By
Application/Therapeutics
12. Asia Pacific Cell and Gene Therapy Consumables Market
Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Asia Pacific
Cell and Gene Therapy Consumables Market Revenue (US$ Mn)
12.2. Asia
Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
12.2.1. Kits
and Buffers
12.2.2. Culture
Medium
12.2.2.1. Natural
Media
12.2.2.1.1. Plasma
12.2.2.1.2. Serum
12.2.2.1.3. Lymph
12.2.2.1.4. Human
Placental Cord Serum
12.2.2.1.5. Amniotic
Fluid
12.2.2.1.6. Others
12.2.2.2. Artificial
Media
12.2.2.2.1. MEM
12.2.2.2.2. RPMI
12.2.2.2.3. PBS
12.2.2.2.4. DPBS
12.2.2.2.5. HBSS
12.2.2.2.6. EBSS
12.2.2.2.7. Others
12.2.3. Cryopreservation
Media
12.2.4. Diagnostic
Assay
12.2.5. Others
12.3. Asia
Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
12.3.1. Cardiovascular
12.3.2. Dermatology
12.3.3. Endocrine
and Metabolic
12.3.4. Gastroenterology
12.3.5. Hematology
and Oncology
12.3.6. Obstetrics
12.3.7. Critical
Care
12.3.8. Immunology
12.3.9. Neuroscience
12.3.10. Respiratory
12.3.11. Urology
12.3.12. Others
12.4. Asia
Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Country
12.4.1. China
12.4.1.1. China
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
12.4.1.1.1. Kits
and Buffers
12.4.1.1.2. Culture
Medium
12.4.1.1.2.1. Natural
Media
12.4.1.1.2.1.1. Plasma
12.4.1.1.2.1.2. Serum
12.4.1.1.2.1.3. Lymph
12.4.1.1.2.1.4. Human Placental Cord Serum
12.4.1.1.2.1.5. Amniotic Fluid
12.4.1.1.2.1.6. Others
12.4.1.1.2.2. Artificial
Media
12.4.1.1.2.2.1. MEM
12.4.1.1.2.2.2. RPMI
12.4.1.1.2.2.3. PBS
12.4.1.1.2.2.4. DPBS
12.4.1.1.2.2.5. HBSS
12.4.1.1.2.2.6. EBSS
12.4.1.1.2.2.7. Others
12.4.1.1.3. Cryopreservation
Media
12.4.1.1.4. Diagnostic
Assay
12.4.1.1.5. Others
12.4.1.2. China
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
12.4.1.2.1. Cardiovascular
12.4.1.2.2. Dermatology
12.4.1.2.3. Endocrine
and Metabolic
12.4.1.2.4. Gastroenterology
12.4.1.2.5. Hematology
and Oncology
12.4.1.2.6. Obstetrics
12.4.1.2.7. Critical
Care
12.4.1.2.8. Immunology
12.4.1.2.9. Neuroscience
12.4.1.2.10. Respiratory
12.4.1.2.11. Urology
12.4.1.2.12. Others
12.4.2. Japan
12.4.2.1. Japan
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
12.4.2.1.1. Kits
and Buffers
12.4.2.1.2. Culture
Medium
12.4.2.1.2.1. Natural
Media
12.4.2.1.2.1.1. Plasma
12.4.2.1.2.1.2. Serum
12.4.2.1.2.1.3. Lymph
12.4.2.1.2.1.4. Human Placental Cord Serum
12.4.2.1.2.1.5. Amniotic Fluid
12.4.2.1.2.1.6. Others
12.4.2.1.2.2. Artificial
Media
12.4.2.1.2.2.1. MEM
12.4.2.1.2.2.2. RPMI
12.4.2.1.2.2.3. PBS
12.4.2.1.2.2.4. DPBS
12.4.2.1.2.2.5. HBSS
12.4.2.1.2.2.6. EBSS
12.4.2.1.2.2.7. Others
12.4.2.1.3. Cryopreservation
Media
12.4.2.1.4. Diagnostic
Assay
12.4.2.1.5. Others
12.4.2.2. Japan
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
12.4.2.2.1. Cardiovascular
12.4.2.2.2. Dermatology
12.4.2.2.3. Endocrine
and Metabolic
12.4.2.2.4. Gastroenterology
12.4.2.2.5. Hematology
and Oncology
12.4.2.2.6. Obstetrics
12.4.2.2.7. Critical
Care
12.4.2.2.8. Immunology
12.4.2.2.9. Neuroscience
12.4.2.2.10. Respiratory
12.4.2.2.11. Urology
12.4.2.2.12. Others
12.4.3. India
12.4.3.1. India
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
12.4.3.1.1. Kits
and Buffers
12.4.3.1.2. Culture
Medium
12.4.3.1.2.1. Natural
Media
12.4.3.1.2.1.1. Plasma
12.4.3.1.2.1.2. Serum
12.4.3.1.2.1.3. Lymph
12.4.3.1.2.1.4. Human Placental Cord Serum
12.4.3.1.2.1.5. Amniotic Fluid
12.4.3.1.2.1.6. Others
12.4.3.1.2.2. Artificial
Media
12.4.3.1.2.2.1. MEM
12.4.3.1.2.2.2. RPMI
12.4.3.1.2.2.3. PBS
12.4.3.1.2.2.4. DPBS
12.4.3.1.2.2.5. HBSS
12.4.3.1.2.2.6. EBSS
12.4.3.1.2.2.7. Others
12.4.3.1.3. Cryopreservation
Media
12.4.3.1.4. Diagnostic
Assay
12.4.3.1.5. Others
12.4.3.2. India
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
12.4.3.2.1. Cardiovascular
12.4.3.2.2. Dermatology
12.4.3.2.3. Endocrine
and Metabolic
12.4.3.2.4. Gastroenterology
12.4.3.2.5. Hematology
and Oncology
12.4.3.2.6. Obstetrics
12.4.3.2.7. Critical
Care
12.4.3.2.8. Immunology
12.4.3.2.9. Neuroscience
12.4.3.2.10. Respiratory
12.4.3.2.11. Urology
12.4.3.2.12. Others
12.4.4. New
Zealand
12.4.4.1. New Zealand
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
12.4.4.1.1. Kits
and Buffers
12.4.4.1.2. Culture
Medium
12.4.4.1.2.1. Natural
Media
12.4.4.1.2.1.1. Plasma
12.4.4.1.2.1.2. Serum
12.4.4.1.2.1.3. Lymph
12.4.4.1.2.1.4. Human Placental Cord Serum
12.4.4.1.2.1.5. Amniotic Fluid
12.4.4.1.2.1.6. Others
12.4.4.1.2.2. Artificial
Media
12.4.4.1.2.2.1. MEM
12.4.4.1.2.2.2. RPMI
12.4.4.1.2.2.3. PBS
12.4.4.1.2.2.4. DPBS
12.4.4.1.2.2.5. HBSS
12.4.4.1.2.2.6. EBSS
12.4.4.1.2.2.7. Others
12.4.4.1.3. Cryopreservation
Media
12.4.4.1.4. Diagnostic
Assay
12.4.4.1.5. Others
12.4.4.2. New
Zealand Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
12.4.4.2.1. Cardiovascular
12.4.4.2.2. Dermatology
12.4.4.2.3. Endocrine
and Metabolic
12.4.4.2.4. Gastroenterology
12.4.4.2.5. Hematology
and Oncology
12.4.4.2.6. Obstetrics
12.4.4.2.7. Critical
Care
12.4.4.2.8. Immunology
12.4.4.2.9. Neuroscience
12.4.4.2.10. Respiratory
12.4.4.2.11. Urology
12.4.4.2.12. Others
12.4.5. Australia
12.4.5.1. Australia
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
12.4.5.1.1. Kits
and Buffers
12.4.5.1.2. Culture
Medium
12.4.5.1.2.1. Natural
Media
12.4.5.1.2.1.1. Plasma
12.4.5.1.2.1.2. Serum
12.4.5.1.2.1.3. Lymph
12.4.5.1.2.1.4. Human Placental Cord Serum
12.4.5.1.2.1.5. Amniotic Fluid
12.4.5.1.2.1.6. Others
12.4.5.1.2.2. Artificial
Media
12.4.5.1.2.2.1. MEM
12.4.5.1.2.2.2. RPMI
12.4.5.1.2.2.3. PBS
12.4.5.1.2.2.4. DPBS
12.4.5.1.2.2.5. HBSS
12.4.5.1.2.2.6. EBSS
12.4.5.1.2.2.7. Others
12.4.5.1.3. Cryopreservation
Media
12.4.5.1.4. Diagnostic
Assay
12.4.5.1.5. Others
12.4.5.2. Australia
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By Application/Therapeutics
12.4.5.2.1. Cardiovascular
12.4.5.2.2. Dermatology
12.4.5.2.3. Endocrine
and Metabolic
12.4.5.2.4. Gastroenterology
12.4.5.2.5. Hematology
and Oncology
12.4.5.2.6. Obstetrics
12.4.5.2.7. Critical
Care
12.4.5.2.8. Immunology
12.4.5.2.9. Neuroscience
12.4.5.2.10. Respiratory
12.4.5.2.11. Urology
12.4.5.2.12. Others
12.4.6. South
Korea
12.4.6.1. South
Korea Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Product Type
12.4.6.1.1. Kits
and Buffers
12.4.6.1.2. Culture
Medium
12.4.6.1.2.1. Natural
Media
12.4.6.1.2.1.1. Plasma
12.4.6.1.2.1.2. Serum
12.4.6.1.2.1.3. Lymph
12.4.6.1.2.1.4. Human Placental Cord Serum
12.4.6.1.2.1.5. Amniotic Fluid
12.4.6.1.2.1.6. Others
12.4.6.1.2.2. Artificial
Media
12.4.6.1.2.2.1. MEM
12.4.6.1.2.2.2. RPMI
12.4.6.1.2.2.3. PBS
12.4.6.1.2.2.4. DPBS
12.4.6.1.2.2.5. HBSS
12.4.6.1.2.2.6. EBSS
12.4.6.1.2.2.7. Others
12.4.6.1.3. Cryopreservation
Media
12.4.6.1.4. Diagnostic
Assay
12.4.6.1.5. Others
12.4.6.2. South
Korea Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Application/Therapeutics
12.4.6.2.1. Cardiovascular
12.4.6.2.2. Dermatology
12.4.6.2.3. Endocrine
and Metabolic
12.4.6.2.4. Gastroenterology
12.4.6.2.5. Hematology
and Oncology
12.4.6.2.6. Obstetrics
12.4.6.2.7. Critical
Care
12.4.6.2.8. Immunology
12.4.6.2.9. Neuroscience
12.4.6.2.10. Respiratory
12.4.6.2.11. Urology
12.4.6.2.12. Others
12.4.7. Southeast
Asia
12.4.7.1. Southeast
Asia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Product Type
12.4.7.1.1. Kits
and Buffers
12.4.7.1.2. Culture
Medium
12.4.7.1.2.1. Natural
Media
12.4.7.1.2.1.1. Plasma
12.4.7.1.2.1.2. Serum
12.4.7.1.2.1.3. Lymph
12.4.7.1.2.1.4. Human Placental Cord Serum
12.4.7.1.2.1.5. Amniotic Fluid
12.4.7.1.2.1.6. Others
12.4.7.1.2.2. Artificial
Media
12.4.7.1.2.2.1. MEM
12.4.7.1.2.2.2. RPMI
12.4.7.1.2.2.3. PBS
12.4.7.1.2.2.4. DPBS
12.4.7.1.2.2.5. HBSS
12.4.7.1.2.2.6. EBSS
12.4.7.1.2.2.7. Others
12.4.7.1.3. Cryopreservation
Media
12.4.7.1.4. Diagnostic
Assay
12.4.7.1.5. Others
12.4.7.2. Southeast
Asia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Application/Therapeutics
12.4.7.2.1. Cardiovascular
12.4.7.2.2. Dermatology
12.4.7.2.3. Endocrine
and Metabolic
12.4.7.2.4. Gastroenterology
12.4.7.2.5. Hematology
and Oncology
12.4.7.2.6. Obstetrics
12.4.7.2.7. Critical
Care
12.4.7.2.8. Immunology
12.4.7.2.9. Neuroscience
12.4.7.2.10. Respiratory
12.4.7.2.11. Urology
12.4.7.2.12. Others
12.4.7.3. Southeast
Asia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest
of Southeast Asia
12.4.8. Rest of
Asia Pacific
12.4.8.1. Rest
of Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
12.4.8.1.1. Kits
and Buffers
12.4.8.1.2. Culture
Medium
12.4.8.1.2.1. Natural
Media
12.4.8.1.2.1.1. Plasma
12.4.8.1.2.1.2. Serum
12.4.8.1.2.1.3. Lymph
12.4.8.1.2.1.4. Human Placental Cord Serum
12.4.8.1.2.1.5. Amniotic Fluid
12.4.8.1.2.1.6. Others
12.4.8.1.2.2. Artificial
Media
12.4.8.1.2.2.1. MEM
12.4.8.1.2.2.2. RPMI
12.4.8.1.2.2.3. PBS
12.4.8.1.2.2.4. DPBS
12.4.8.1.2.2.5. HBSS
12.4.8.1.2.2.6. EBSS
12.4.8.1.2.2.7. Others
12.4.8.1.3. Cryopreservation
Media
12.4.8.1.4. Diagnostic
Assay
12.4.8.1.5. Others
12.4.8.2. Rest
of Asia Pacific Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
12.4.8.2.1. Cardiovascular
12.4.8.2.2. Dermatology
12.4.8.2.3. Endocrine
and Metabolic
12.4.8.2.4. Gastroenterology
12.4.8.2.5. Hematology
and Oncology
12.4.8.2.6. Obstetrics
12.4.8.2.7. Critical
Care
12.4.8.2.8. Immunology
12.4.8.2.9. Neuroscience
12.4.8.2.10. Respiratory
12.4.8.2.11. Urology
12.4.8.2.12. Others
12.5. Key
Segment for Channeling Investments
12.5.1. By
Country
12.5.2. By
Product Type
12.5.3. By
Application/Therapeutics
13. Middle East and Africa Cell and Gene Therapy Consumables
Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Middle
East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn)
13.2. Middle
East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
13.2.1. Kits
and Buffers
13.2.2. Culture
Medium
13.2.2.1. Natural
Media
13.2.2.1.1. Plasma
13.2.2.1.2. Serum
13.2.2.1.3. Lymph
13.2.2.1.4. Human
Placental Cord Serum
13.2.2.1.5. Amniotic
Fluid
13.2.2.1.6. Others
13.2.2.2. Artificial
Media
13.2.2.2.1. MEM
13.2.2.2.2. RPMI
13.2.2.2.3. PBS
13.2.2.2.4. DPBS
13.2.2.2.5. HBSS
13.2.2.2.6. EBSS
13.2.2.2.7. Others
13.2.3. Cryopreservation
Media
13.2.4. Diagnostic
Assay
13.2.5. Others
13.3. Middle
East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
13.3.1. Cardiovascular
13.3.2. Dermatology
13.3.3. Endocrine
and Metabolic
13.3.4. Gastroenterology
13.3.5. Hematology
and Oncology
13.3.6. Obstetrics
13.3.7. Critical
Care
13.3.8. Immunology
13.3.9. Neuroscience
13.3.10. Respiratory
13.3.11. Urology
13.3.12. Others
13.4. Middle
East and Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Country
13.4.1. Saudi
Arabia
13.4.1.1. Saudi
Arabia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Product Type
13.4.1.1.1. Kits
and Buffers
13.4.1.1.2. Culture
Medium
13.4.1.1.2.1. Natural
Media
13.4.1.1.2.1.1. Plasma
13.4.1.1.2.1.2. Serum
13.4.1.1.2.1.3. Lymph
13.4.1.1.2.1.4. Human Placental Cord Serum
13.4.1.1.2.1.5. Amniotic Fluid
13.4.1.1.2.1.6. Others
13.4.1.1.2.2. Artificial
Media
13.4.1.1.2.2.1. MEM
13.4.1.1.2.2.2. RPMI
13.4.1.1.2.2.3. PBS
13.4.1.1.2.2.4. DPBS
13.4.1.1.2.2.5. HBSS
13.4.1.1.2.2.6. EBSS
13.4.1.1.2.2.7. Others
13.4.1.1.3. Cryopreservation
Media
13.4.1.1.4. Diagnostic
Assay
13.4.1.1.5. Others
13.4.1.2. Saudi
Arabia Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Application/Therapeutics
13.4.1.2.1. Cardiovascular
13.4.1.2.2. Dermatology
13.4.1.2.3. Endocrine
and Metabolic
13.4.1.2.4. Gastroenterology
13.4.1.2.5. Hematology
and Oncology
13.4.1.2.6. Obstetrics
13.4.1.2.7. Critical
Care
13.4.1.2.8. Immunology
13.4.1.2.9. Neuroscience
13.4.1.2.10. Respiratory
13.4.1.2.11. Urology
13.4.1.2.12. Others
13.4.2. UAE
13.4.2.1. UAE
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
13.4.2.1.1. Kits
and Buffers
13.4.2.1.2. Culture
Medium
13.4.2.1.2.1. Natural
Media
13.4.2.1.2.1.1. Plasma
13.4.2.1.2.1.2. Serum
13.4.2.1.2.1.3. Lymph
13.4.2.1.2.1.4. Human Placental Cord Serum
13.4.2.1.2.1.5. Amniotic Fluid
13.4.2.1.2.1.6. Others
13.4.2.1.2.2. Artificial
Media
13.4.2.1.2.2.1. MEM
13.4.2.1.2.2.2. RPMI
13.4.2.1.2.2.3. PBS
13.4.2.1.2.2.4. DPBS
13.4.2.1.2.2.5. HBSS
13.4.2.1.2.2.6. EBSS
13.4.2.1.2.2.7. Others
13.4.2.1.3. Cryopreservation
Media
13.4.2.1.4. Diagnostic
Assay
13.4.2.1.5. Others
13.4.2.2. UAE
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
13.4.2.2.1. Cardiovascular
13.4.2.2.2. Dermatology
13.4.2.2.3. Endocrine
and Metabolic
13.4.2.2.4. Gastroenterology
13.4.2.2.5. Hematology
and Oncology
13.4.2.2.6. Obstetrics
13.4.2.2.7. Critical
Care
13.4.2.2.8. Immunology
13.4.2.2.9. Neuroscience
13.4.2.2.10. Respiratory
13.4.2.2.11. Urology
13.4.2.2.12. Others
13.4.3. Egypt
13.4.3.1. Egypt
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
13.4.3.1.1. Kits
and Buffers
13.4.3.1.2. Culture
Medium
13.4.3.1.2.1. Natural
Media
13.4.3.1.2.1.1. Plasma
13.4.3.1.2.1.2. Serum
13.4.3.1.2.1.3. Lymph
13.4.3.1.2.1.4. Human Placental Cord Serum
13.4.3.1.2.1.5. Amniotic Fluid
13.4.3.1.2.1.6. Others
13.4.3.1.2.2. Artificial
Media
13.4.3.1.2.2.1. MEM
13.4.3.1.2.2.2. RPMI
13.4.3.1.2.2.3. PBS
13.4.3.1.2.2.4. DPBS
13.4.3.1.2.2.5. HBSS
13.4.3.1.2.2.6. EBSS
13.4.3.1.2.2.7. Others
13.4.3.1.3. Cryopreservation
Media
13.4.3.1.4. Diagnostic
Assay
13.4.3.1.5. Others
13.4.3.2. Egypt
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
13.4.3.2.1. Cardiovascular
13.4.3.2.2. Dermatology
13.4.3.2.3. Endocrine
and Metabolic
13.4.3.2.4. Gastroenterology
13.4.3.2.5. Hematology
and Oncology
13.4.3.2.6. Obstetrics
13.4.3.2.7. Critical
Care
13.4.3.2.8. Immunology
13.4.3.2.9. Neuroscience
13.4.3.2.10. Respiratory
13.4.3.2.11. Urology
13.4.3.2.12. Others
13.4.4. Kuwait
13.4.4.1. Kuwait
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
13.4.4.1.1. Kits
and Buffers
13.4.4.1.2. Culture
Medium
13.4.4.1.2.1. Natural
Media
13.4.4.1.2.1.1. Plasma
13.4.4.1.2.1.2. Serum
13.4.4.1.2.1.3. Lymph
13.4.4.1.2.1.4. Human Placental Cord Serum
13.4.4.1.2.1.5. Amniotic Fluid
13.4.4.1.2.1.6. Others
13.4.4.1.2.2. Artificial
Media
13.4.4.1.2.2.1. MEM
13.4.4.1.2.2.2. RPMI
13.4.4.1.2.2.3. PBS
13.4.4.1.2.2.4. DPBS
13.4.4.1.2.2.5. HBSS
13.4.4.1.2.2.6. EBSS
13.4.4.1.2.2.7. Others
13.4.4.1.3. Cryopreservation
Media
13.4.4.1.4. Diagnostic
Assay
13.4.4.1.5. Others
13.4.4.2. Kuwait
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
13.4.4.2.1. Cardiovascular
13.4.4.2.2. Dermatology
13.4.4.2.3. Endocrine
and Metabolic
13.4.4.2.4. Gastroenterology
13.4.4.2.5. Hematology
and Oncology
13.4.4.2.6. Obstetrics
13.4.4.2.7. Critical
Care
13.4.4.2.8. Immunology
13.4.4.2.9. Neuroscience
13.4.4.2.10. Respiratory
13.4.4.2.11. Urology
13.4.4.2.12. Others
13.4.5. South
Africa
13.4.5.1. South
Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Product Type
13.4.5.1.1. Kits
and Buffers
13.4.5.1.2. Culture
Medium
13.4.5.1.2.1. Natural
Media
13.4.5.1.2.1.1. Plasma
13.4.5.1.2.1.2. Serum
13.4.5.1.2.1.3. Lymph
13.4.5.1.2.1.4. Human Placental Cord Serum
13.4.5.1.2.1.5. Amniotic Fluid
13.4.5.1.2.1.6. Others
13.4.5.1.2.2. Artificial
Media
13.4.5.1.2.2.1. MEM
13.4.5.1.2.2.2. RPMI
13.4.5.1.2.2.3. PBS
13.4.5.1.2.2.4. DPBS
13.4.5.1.2.2.5. HBSS
13.4.5.1.2.2.6. EBSS
13.4.5.1.2.2.7. Others
13.4.5.1.3. Cryopreservation
Media
13.4.5.1.4. Diagnostic
Assay
13.4.5.1.5. Others
13.4.5.2. South
Africa Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts,
By Application/Therapeutics
13.4.5.2.1. Cardiovascular
13.4.5.2.2. Dermatology
13.4.5.2.3. Endocrine
and Metabolic
13.4.5.2.4. Gastroenterology
13.4.5.2.5. Hematology
and Oncology
13.4.5.2.6. Obstetrics
13.4.5.2.7. Critical
Care
13.4.5.2.8. Immunology
13.4.5.2.9. Neuroscience
13.4.5.2.10. Respiratory
13.4.5.2.11. Urology
13.4.5.2.12. Others
13.4.6. Rest of
Middle East & Africa
13.4.6.1. Rest
of Middle East & Africa Cell and Gene Therapy Consumables Market Revenue
(US$ Mn) and Forecasts, By Product Type
13.4.6.1.1. Kits
and Buffers
13.4.6.1.2. Culture
Medium
13.4.6.1.2.1. Natural
Media
13.4.6.1.2.1.1. Plasma
13.4.6.1.2.1.2. Serum
13.4.6.1.2.1.3. Lymph
13.4.6.1.2.1.4. Human Placental Cord Serum
13.4.6.1.2.1.5. Amniotic Fluid
13.4.6.1.2.1.6. Others
13.4.6.1.2.2. Artificial
Media
13.4.6.1.2.2.1. MEM
13.4.6.1.2.2.2. RPMI
13.4.6.1.2.2.3. PBS
13.4.6.1.2.2.4. DPBS
13.4.6.1.2.2.5. HBSS
13.4.6.1.2.2.6. EBSS
13.4.6.1.2.2.7. Others
13.4.6.1.3. Cryopreservation
Media
13.4.6.1.4. Diagnostic
Assay
13.4.6.1.5. Others
13.4.6.2. Rest
of Middle East & Africa Cell and Gene Therapy Consumables Market Revenue
(US$ Mn) and Forecasts, By Application/Therapeutics
13.4.6.2.1. Cardiovascular
13.4.6.2.2. Dermatology
13.4.6.2.3. Endocrine
and Metabolic
13.4.6.2.4. Gastroenterology
13.4.6.2.5. Hematology
and Oncology
13.4.6.2.6. Obstetrics
13.4.6.2.7. Critical
Care
13.4.6.2.8. Immunology
13.4.6.2.9. Neuroscience
13.4.6.2.10. Respiratory
13.4.6.2.11. Urology
13.4.6.2.12. Others
13.5. Key
Segment for Channeling Investments
13.5.1. By
Country
13.5.2. By
Product Type
13.5.3. By
Application/Therapeutics
14. Latin America Cell and Gene Therapy Consumables Market
Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Latin
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn)
14.2. Latin
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
14.2.1. Kits
and Buffers
14.2.2. Culture
Medium
14.2.2.1. Natural
Media
14.2.2.1.1. Plasma
14.2.2.1.2. Serum
14.2.2.1.3. Lymph
14.2.2.1.4. Human
Placental Cord Serum
14.2.2.1.5. Amniotic
Fluid
14.2.2.1.6. Others
14.2.2.2. Artificial
Media
14.2.2.2.1. MEM
14.2.2.2.2. RPMI
14.2.2.2.3. PBS
14.2.2.2.4. DPBS
14.2.2.2.5. HBSS
14.2.2.2.6. EBSS
14.2.2.2.7. Others
14.2.3. Cryopreservation
Media
14.2.4. Diagnostic
Assay
14.2.5. Others
14.3. Latin
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
14.3.1. Cardiovascular
14.3.2. Dermatology
14.3.3. Endocrine
and Metabolic
14.3.4. Gastroenterology
14.3.5. Hematology
and Oncology
14.3.6. Obstetrics
14.3.7. Critical
Care
14.3.8. Immunology
14.3.9. Neuroscience
14.3.10. Respiratory
14.3.11. Urology
14.3.12. Others
14.4. Latin
America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
14.4.1.1.1. Kits
and Buffers
14.4.1.1.2. Culture
Medium
14.4.1.1.2.1. Natural
Media
14.4.1.1.2.1.1. Plasma
14.4.1.1.2.1.2. Serum
14.4.1.1.2.1.3. Lymph
14.4.1.1.2.1.4. Human Placental Cord Serum
14.4.1.1.2.1.5. Amniotic Fluid
14.4.1.1.2.1.6. Others
14.4.1.1.2.2. Artificial
Media
14.4.1.1.2.2.1. MEM
14.4.1.1.2.2.2. RPMI
14.4.1.1.2.2.3. PBS
14.4.1.1.2.2.4. DPBS
14.4.1.1.2.2.5. HBSS
14.4.1.1.2.2.6. EBSS
14.4.1.1.2.2.7. Others
14.4.1.1.3. Cryopreservation
Media
14.4.1.1.4. Diagnostic
Assay
14.4.1.1.5. Others
14.4.1.2. Brazil
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
14.4.1.2.1. Cardiovascular
14.4.1.2.2. Dermatology
14.4.1.2.3. Endocrine
and Metabolic
14.4.1.2.4. Gastroenterology
14.4.1.2.5. Hematology
and Oncology
14.4.1.2.6. Obstetrics
14.4.1.2.7. Critical
Care
14.4.1.2.8. Immunology
14.4.1.2.9. Neuroscience
14.4.1.2.10. Respiratory
14.4.1.2.11. Urology
14.4.1.2.12. Others
14.4.2. Argentina
14.4.2.1. Argentina
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Product Type
14.4.2.1.1. Kits
and Buffers
14.4.2.1.2. Culture
Medium
14.4.2.1.2.1. Natural
Media
14.4.2.1.2.1.1. Plasma
14.4.2.1.2.1.2. Serum
14.4.2.1.2.1.3. Lymph
14.4.2.1.2.1.4. Human Placental Cord Serum
14.4.2.1.2.1.5. Amniotic Fluid
14.4.2.1.2.1.6. Others
14.4.2.1.2.2. Artificial
Media
14.4.2.1.2.2.1. MEM
14.4.2.1.2.2.2. RPMI
14.4.2.1.2.2.3. PBS
14.4.2.1.2.2.4. DPBS
14.4.2.1.2.2.5. HBSS
14.4.2.1.2.2.6. EBSS
14.4.2.1.2.2.7. Others
14.4.2.1.3. Cryopreservation
Media
14.4.2.1.4. Diagnostic
Assay
14.4.2.1.5. Others
14.4.2.2. Argentina
Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and Forecasts, By
Application/Therapeutics
14.4.2.2.1. Cardiovascular
14.4.2.2.2. Dermatology
14.4.2.2.3. Endocrine
and Metabolic
14.4.2.2.4. Gastroenterology
14.4.2.2.5. Hematology
and Oncology
14.4.2.2.6. Obstetrics
14.4.2.2.7. Critical
Care
14.4.2.2.8. Immunology
14.4.2.2.9. Neuroscience
14.4.2.2.10. Respiratory
14.4.2.2.11. Urology
14.4.2.2.12. Others
14.4.3. Rest of
Latin America
14.4.3.1. Rest
of Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Product Type
14.4.3.1.1. Kits
and Buffers
14.4.3.1.2. Culture
Medium
14.4.3.1.2.1. Natural
Media
14.4.3.1.2.1.1. Plasma
14.4.3.1.2.1.2. Serum
14.4.3.1.2.1.3. Lymph
14.4.3.1.2.1.4. Human Placental Cord Serum
14.4.3.1.2.1.5. Amniotic Fluid
14.4.3.1.2.1.6. Others
14.4.3.1.2.2. Artificial
Media
14.4.3.1.2.2.1. MEM
14.4.3.1.2.2.2. RPMI
14.4.3.1.2.2.3. PBS
14.4.3.1.2.2.4. DPBS
14.4.3.1.2.2.5. HBSS
14.4.3.1.2.2.6. EBSS
14.4.3.1.2.2.7. Others
14.4.3.1.3. Cryopreservation
Media
14.4.3.1.4. Diagnostic
Assay
14.4.3.1.5. Others
14.4.3.2. Rest
of Latin America Cell and Gene Therapy Consumables Market Revenue (US$ Mn) and
Forecasts, By Application/Therapeutics
14.4.3.2.1. Cardiovascular
14.4.3.2.2. Dermatology
14.4.3.2.3. Endocrine
and Metabolic
14.4.3.2.4. Gastroenterology
14.4.3.2.5. Hematology
and Oncology
14.4.3.2.6. Obstetrics
14.4.3.2.7. Critical
Care
14.4.3.2.8. Immunology
14.4.3.2.9. Neuroscience
14.4.3.2.10. Respiratory
14.4.3.2.11. Urology
14.4.3.2.12. Others
14.5. Key
Segment for Channeling Investments
14.5.1. By
Country
14.5.2. By
Product Type
14.5.3. By
Application/Therapeutics
15. Competitive Benchmarking
15.1. Market
Share Analysis, 2018
15.2. Global
Presence and Growth Strategies
15.2.1. Mergers
and Acquisitions
15.2.2. Product
Launches
15.2.3. Investments
Trends
15.2.4. R&D
Initiatives
16. Player Profiles
16.1. Amgen
Inc.
16.1.1. Company
Details
16.1.2. Company
Overview
16.1.3. Product
Offerings
16.1.4. Key
Developments
16.1.5. Financial
Analysis
16.1.6. SWOT
Analysis
16.1.7. Business
Strategies
16.2. ATLANTA
BIOLOGICALS
16.2.1. Company
Details
16.2.2. Company
Overview
16.2.3. Product
Offerings
16.2.4. Key
Developments
16.2.5. Financial
Analysis
16.2.6. SWOT
Analysis
16.2.7. Business
Strategies
16.3. bluebird
bio, Inc.
16.3.1. Company
Details
16.3.2. Company
Overview
16.3.3. Product
Offerings
16.3.4. Key
Developments
16.3.5. Financial
Analysis
16.3.6. SWOT
Analysis
16.3.7. Business
Strategies
16.4. Cook
16.4.1. Company
Details
16.4.2. Company
Overview
16.4.3. Product
Offerings
16.4.4. Key
Developments
16.4.5. Financial
Analysis
16.4.6. SWOT
Analysis
16.4.7. Business
Strategies
16.5. Dendreon
Pharmaceuticals LLC.
16.5.1. Company
Details
16.5.2. Company
Overview
16.5.3. Product
Offerings
16.5.4. Key
Developments
16.5.5. Financial
Analysis
16.5.6. SWOT
Analysis
16.5.7. Business
Strategies
16.6. Fibrocell
Science, Inc.
16.6.1. Company
Details
16.6.2. Company
Overview
16.6.3. Product
Offerings
16.6.4. Key
Developments
16.6.5. Financial
Analysis
16.6.6. SWOT
Analysis
16.6.7. Business
Strategies
16.7. General
Electric
16.7.1. Company
Details
16.7.2. Company
Overview
16.7.3. Product
Offerings
16.7.4. Key
Developments
16.7.5. Financial
Analysis
16.7.6. SWOT Analysis
16.7.7. Business
Strategies
16.8. Kolon
TissueGene, Inc.
16.8.1. Company
Details
16.8.2. Company
Overview
16.8.3. Product
Offerings
16.8.4. Key
Developments
16.8.5. Financial
Analysis
16.8.6. SWOT
Analysis
16.8.7. Business
Strategies
16.9. Orchard
Therapeutics plc.
16.9.1. Company
Details
16.9.2. Company
Overview
16.9.3. Product
Offerings
16.9.4. Key Developments
16.9.5. Financial
Analysis
16.9.6. SWOT
Analysis
16.9.7. Business
Strategies
16.10. Pfizer,
Inc.
16.10.1. Company
Details
16.10.2. Company
Overview
16.10.3. Product
Offerings
16.10.4. Key
Developments
16.10.5. Financial
Analysis
16.10.6. SWOT
Analysis
16.10.7. Business
Strategies
16.11. PromoCell
GmbH
16.11.1. Company
Details
16.11.2. Company
Overview
16.11.3. Product
Offerings
16.11.4. Key
Developments
16.11.5. Financial
Analysis
16.11.6. SWOT
Analysis
16.11.7. Business
Strategies
16.12. RENOVA
THERAPEUTICS
16.12.1. Company
Details
16.12.2. Company
Overview
16.12.3. Product
Offerings
16.12.4. Key
Developments
16.12.5. Financial
Analysis
16.12.6. SWOT
Analysis
16.12.7. Business
Strategies
16.13. Sibiono
GeneTech Co. Ltd.
16.13.1. Company
Details
16.13.2. Company
Overview
16.13.3. Product
Offerings
16.13.4. Key
Developments
16.13.5. Financial
Analysis
16.13.6. SWOT
Analysis
16.13.7. Business
Strategies
16.14. Spark
Therapeutics, Inc.
16.14.1. Company
Details
16.14.2. Company
Overview
16.14.3. Product
Offerings
16.14.4. Key
Developments
16.14.5. Financial
Analysis
16.14.6. SWOT
Analysis
16.14.7. Business
Strategies
16.15. Vericel
16.15.1. Company
Details
16.15.2. Company
Overview
16.15.3. Product
Offerings
16.15.4. Key
Developments
16.15.5. Financial
Analysis
16.15.6. SWOT
Analysis
16.15.7. Business
Strategies
16.16. ViroMed
Co., Ltd.
16.16.1. Company
Details
16.16.2. Company
Overview
16.16.3. Product
Offerings
16.16.4. Key
Developments
16.16.5. Financial
Analysis
16.16.6. SWOT Analysis
16.16.7. Business
Strategies
16.17. Vitrolife
16.17.1. Company
Details
16.17.2. Company
Overview
16.17.3. Product
Offerings
16.17.4. Key
Developments
16.17.5. Financial
Analysis
16.17.6. SWOT
Analysis
16.17.7. Business Strategies
16.18. Other Market Participants
17. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com


Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.
